Skip to content

Study · Observational study · n = 14 · 2024

7 results

Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis.

Otsuka E, Kitamura M, Funakoshi S, Mukae H, Nishino T

Frontiers in pharmacology30 May 2024Cited by 5 (Europe PMC)

PMID38873429 (opens in a new tab)PMCIDPMC11169618 (opens in a new tab)DOI10.3389/fphar.2024.1362242 (opens in a new tab)PepBankPUB-38873429
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

Background: Tirzepatide-a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist-is used to treat type 2 diabetes. However, the efficacy and safety of tirzepatide in patients undergoing hemodialysis remain unclear. Methods: We conducted a single-center retrospective study of patients with type 2 diabetes undergoing hemodialysis who were transitioned from dulaglutide to tirzepatide. We continuously monitored glucose levels in patients undergoing hemodialysis before and after switching from dulaglutide to tirzepatide. Results: Fourteen patients (mean age: 61.9 ± 9.9 years, male: female = 11:3) were included in this study. After switching to tirzepatide, time in range increased to 50.8% from 42.7% (p = 0.02), time above range decreased to 37.8% from 48.4% (p = 0.02), and mean glucose levels decreased to 137.4 mg/dL from 156.6 mg/dL (p = 0.006). In contrast, there was no significant difference in time below range before and after tirzepatide administration (11.3% and 8.9%) (p = 0.75). Three patients experienced dyspepsia (21.4%), and one patient experienced nausea (7.1%); however, no critical adverse events were reported. Conclusion: Transitioning from dulaglutide to tirzepatide improved glycemic control without increasing hypoglycemia in patients undergoing hemodialysis for type 2 diabetes.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In hemodialysis patients with diabetes, switching from dulaglutide to tirzepatide was linked to increased time in range.

    In plain wordsIn dialysis patients with diabetes, switching to tirzepatide was linked to more time within glucose targets than during dulaglutide treatment.

    Peptide
    Tirzepatide
    Outcome
    IncreaseTime in range
    Study

    n = 14

    Comparator
    Before switching, on dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Time in range
    50.8%
    after switch
    Time in range
    42.7%
    before switch

    Source sentences

    Summary
    After switching to tirzepatide, time in range increased to 50.8% from 42.7% (p = 0.02),
    2 context sentences
    Summary · context
    We conducted a single-center retrospective study of patients with type 2 diabetes undergoing hemodialysis who were transitioned from dulaglutide to tirzepatide.
    Summary · context
    Fourteen patients (mean age: 61.9 ± 9.9 years, male: female = 11:3) were included in this study.
  2. 02HumanObservational studyEfficacy outcome

    In hemodialysis patients with diabetes, switching from dulaglutide to tirzepatide was linked to decreased time above range.

    In plain wordsIn dialysis patients with diabetes, switching to tirzepatide was linked to less time above glucose targets than during dulaglutide treatment.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTime above range
    Study

    n = 14

    Comparator
    Before switching, on dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Time above range
    37.8%
    after switch
    Time above range
    48.4%
    before switch

    Source sentences

    Summary
    time above range decreased to 37.8% from 48.4% (p = 0.02), and
    2 context sentences
    Summary · context
    We conducted a single-center retrospective study of patients with type 2 diabetes undergoing hemodialysis who were transitioned from dulaglutide to tirzepatide.
    Summary · context
    Fourteen patients (mean age: 61.9 ± 9.9 years, male: female = 11:3) were included in this study.
  3. 03HumanObservational studyEfficacy outcome

    In hemodialysis patients with diabetes, switching from dulaglutide to tirzepatide was linked to decreased mean glucose.

    In plain wordsIn dialysis patients with diabetes, switching to tirzepatide was linked to lower average glucose than during dulaglutide treatment.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMean glucose
    Study

    n = 14

    Comparator
    Before switching, on dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean glucose
    137.4 mg/dL
    after switch
    Mean glucose
    156.6 mg/dL
    before switch

    Source sentences

    Summary
    mean glucose levels decreased to 137.4 mg/dL from 156.6 mg/dL (p = 0.006).
    2 context sentences
    Summary · context
    We conducted a single-center retrospective study of patients with type 2 diabetes undergoing hemodialysis who were transitioned from dulaglutide to tirzepatide.
    Summary · context
    Fourteen patients (mean age: 61.9 ± 9.9 years, male: female = 11:3) were included in this study.
  4. 04HumanObservational studySafety outcome

    In hemodialysis patients with diabetes, time below range did not differ significantly after switching from dulaglutide to tirzepatide.

    In plain wordsIn dialysis patients with diabetes, time below glucose targets did not differ significantly between dulaglutide and subsequent tirzepatide treatment.

    Peptide
    Tirzepatide
    Outcome
    No significant changeTime below range
    Study

    n = 14

    Comparator
    Before switching, on dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Time below range
    11.3%
    before switch
    Time below range
    8.9%
    after switch

    Source sentences

    Summary
    In contrast, there was no significant difference in time below range before and after tirzepatide administration (11.3% and 8.9%) (p = 0.75).
    2 context sentences
    Summary · context
    We conducted a single-center retrospective study of patients with type 2 diabetes undergoing hemodialysis who were transitioned from dulaglutide to tirzepatide.
    Summary · context
    Fourteen patients (mean age: 61.9 ± 9.9 years, male: female = 11:3) were included in this study.
  5. 05HumanObservational studySafety outcome

    In hemodialysis patients switched to tirzepatide, three patients reported dyspepsia (21.4%).

    In plain wordsIn dialysis patients switched to tirzepatide, three patients reported indigestion.

    Peptide
    Tirzepatide
    Outcome
    Not applicableDyspepsia
    Study

    n = 14

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Dyspepsia
    3 patients
    tirzepatide
    Dyspepsia
    21.4%
    tirzepatide

    Source sentences

    Summary
    Three patients experienced dyspepsia (21.4%), and one patient experienced nausea (7.1%); however, no critical adverse events were reported.
    2 context sentences
    Summary · context
    We conducted a single-center retrospective study of patients with type 2 diabetes undergoing hemodialysis who were transitioned from dulaglutide to tirzepatide.
    Summary · context
    Fourteen patients (mean age: 61.9 ± 9.9 years, male: female = 11:3) were included in this study.
  6. 06HumanObservational studySafety outcome

    In hemodialysis patients switched to tirzepatide, one patient reported nausea (7.1%).

    In plain wordsIn dialysis patients switched to tirzepatide, one patient reported nausea.

    Peptide
    Tirzepatide
    Outcome
    Not applicableNausea
    Study

    n = 14

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Nausea
    1 patient
    tirzepatide
    Nausea
    7.1%
    tirzepatide

    Source sentences

    Summary
    Three patients experienced dyspepsia (21.4%), and one patient experienced nausea (7.1%); however, no critical adverse events were reported.
    2 context sentences
    Summary · context
    We conducted a single-center retrospective study of patients with type 2 diabetes undergoing hemodialysis who were transitioned from dulaglutide to tirzepatide.
    Summary · context
    Fourteen patients (mean age: 61.9 ± 9.9 years, male: female = 11:3) were included in this study.
  7. 07HumanObservational studySafety outcome

    In hemodialysis patients switched to tirzepatide, no critical adverse events were reported.

    In plain wordsIn dialysis patients switched to tirzepatide, no critical adverse events were reported.

    Peptide
    Tirzepatide
    Outcome
    Not applicableCritical adverse events
    Study

    n = 14

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Three patients experienced dyspepsia (21.4%), and one patient experienced nausea (7.1%); however, no critical adverse events were reported.
    2 context sentences
    Summary · context
    We conducted a single-center retrospective study of patients with type 2 diabetes undergoing hemodialysis who were transitioned from dulaglutide to tirzepatide.
    Summary · context
    Fourteen patients (mean age: 61.9 ± 9.9 years, male: female = 11:3) were included in this study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.